Assessing Erasca (ERAS) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]
Erasca, Inc. (ERAS)
Company Research
Source: Yahoo! Finance
What recent performance suggests about Erasca shares Erasca (ERAS) has caught investor attention after a sharp move in the stock over the past month, with shares closing at US$13.66 and showing very large total returns over the past 3 months. See our latest analysis for Erasca. That recent 30-day share price return of around 30% sits on top of strong year-to-date momentum, and the very large one year total shareholder return suggests sentiment around Erasca's pipeline has shifted meaningfully. If Erasca's move has you thinking about where else growth stories might be emerging in healthcare, it could be worth scanning our list of 28 healthcare AI stocks as a starting point for fresh ideas. With Erasca now at US$13.66 after a very large one year total return, and the current price sitting above the average analyst target of US$11.56, you have to ask whether there is still a buying opportunity here or whether the market is already pricing in future growth. Preferred Price-to
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Tango rises after Q4 results, clinical pact with Erasca [Seeking Alpha]Seeking Alpha
- Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]Yahoo! Finance
- Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat [Yahoo! Finance]Yahoo! Finance
- Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and VopimetostatGlobeNewswire
- Erasca Conference: ERAS Teases 2026 Catalysts for Pan-RAS ERAS-0015 and Pan-KRAS ERAS-4001 [Yahoo! Finance]Yahoo! Finance
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 3/6/26 - Form 4
- 3/4/26 - Form 144
- 2/17/26 - Form 144
- ERAS's page on the SEC website